{"groups":[{"description":"Participants were treated with lanreotide 120mg and assigned to Group 2 (before starting on Pasireotide in the Core phase).","id":"FG000","title":"Lanreotide 120 mg"},{"description":"Participants were treated with octreotide 30 mg and assigned to Group 2 (before starting on Pasireotide in the Core phase). .","id":"FG001","title":"Octreotide 30 mg"},{"description":"Participants were treated with octreotide 40 mg and assigned to either Group 1 (if 40mg octreotide was approved in the country) or Group 2 if 40mg octreotide was not approved in the country (before starting on Pasireotide in the Core phase).","id":"FG002","title":"Octreotide 40 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}],"type":"Unsatisfactory therapeutic effect"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"41"},{"groupId":"FG001","numSubjects":"29"},{"groupId":"FG002","numSubjects":"53"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"39"},{"groupId":"FG001","numSubjects":"27"},{"groupId":"FG002","numSubjects":"47"}],"comment":"Completed 36 week (wk) Core phase","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"6"}],"type":"NOT COMPLETED"}],"title":"Period 1: Core Phase"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"}],"type":"Unsatisfactory therapeutic effect"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"comment":"not all patients who completed the Core phase went into the Extension phase","groupId":"FG000","numSubjects":"26"},{"comment":"not all patients who completed the Core phase went into the Extension phase","groupId":"FG001","numSubjects":"23"},{"comment":"not all patients who completed the Core phase went into the Extension phase","groupId":"FG002","numSubjects":"39"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"19"},{"groupId":"FG002","numSubjects":"36"}],"comment":"Completed 72 week extension phase","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Period 2: Extension Phase"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"}],"type":"Unsatisfactory therapeutic effect"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"23"},{"groupId":"FG002","numSubjects":"39"}],"comment":"Entered post-treatment follow up","type":"STARTED"},{"achievements":[{"comment":"Entered post-treatment follow-up, discontinued","groupId":"FG000","numSubjects":"4"},{"comment":"Entered post-treatment follow-up, discontinued","groupId":"FG001","numSubjects":"3"},{"comment":"Entered post-treatment follow-up, discontinued","groupId":"FG002","numSubjects":"3"}],"type":"Entered Post-treatment f/up Discontinued"},{"achievements":[{"comment":"Entered post-treatment follow-up, completed","groupId":"FG000","numSubjects":"22"},{"comment":"Entered post-treatment follow-up, completed","groupId":"FG001","numSubjects":"20"},{"comment":"Entered post-treatment follow-up, completed","groupId":"FG002","numSubjects":"36"}],"comment":"Entered post-treatment follow-up, completed","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Period 3: Post-treatment Follow up Phase"}],"preAssignmentDetails":"Participants were allocated to Group 1 or Group 2 based on previously received first generation Somatostatin analog (SSA).","recruitmentDetails":"Planned 112 participants and analyzed 123 participants. For Participant Flow/Baseline Characteristics Tables, Total = Participants in the Pasireotide LAR arm."}